Caricamento...
Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report
RATIONALE: Lung cancer is the leading cause of cancer-related death in the world. Tyrosine kinase inhibitors (TKIs), which target mutated epidermal growth factor receptor (EGFR), have been the first-line treatment of late-stage lung adenocarcinoma harboring EGFR mutation. EGFR mutations are mostly i...
Salvato in:
| Pubblicato in: | Medicine (Baltimore) |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wolters Kluwer Health
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5457885/ https://ncbi.nlm.nih.gov/pubmed/28538405 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000006985 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|